Loading stock data...

Gujarat Terce Laboratories Limited

BSE: GUJTERC

BSE
42.41 -1.45 (-3.31%)

Prev Close

43.86

Open Price

46.5

Volume

6,785

Today Low / High

42.08 / 48

52 WK Low / High

37.2 / 88.6

Range

40 - 45

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 42.41, reflecting a change of -1.45 (-3.30597%). The expected target range on the BSE is 40 - 45. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

29 Sep 46.50 -8.80%
26 Sep 40.00 9.65%
25 Sep 42.50 -4.73%
24 Sep 42.50 1.08%
23 Sep 41.59 2.19%
22 Sep 42.48 -2.07%
19 Sep 44.50 -8.34%
18 Sep 40.75 -1.84%
17 Sep 40.55 -0.07%
16 Sep 40.95 2.25%
15 Sep 41.50 -3.25%
12 Sep 40.70 -1.72%
11 Sep 40.20 -0.40%
10 Sep 40.00 0.50%
09 Sep 40.00 0.02%
08 Sep 42.00 -5.12%
05 Sep 38.16 5.35%
04 Sep 39.77 0.23%
03 Sep 38.00 4.61%
02 Sep 40.00 -4.10%
01 Sep 40.75 -0.37%

Gujarat Terce Laboratories Limited Graph

Gujarat Terce Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Gujarat Terce Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 42.41, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 42.41 42.83 38.55 - 47.12
43.26 34.61 - 51.91
43.68 30.58 - 56.79
Bearish Scenario 42.41 41.99 37.79 - 46.18
41.56 33.25 - 49.87
41.14 28.80 - 53.48

Overview of Gujarat Terce Laboratories Limited

ISIN

INE499G01013

Industry

Medical - Pharmaceuticals

Vol.Avg

6,780

Market Cap

314,694,923

Last Dividend

0

Official Website

Visit Website

IPO Date

DCF Diff

73.42

DCF

-31

Financial Ratios Every Investor Needs

Stock Rating Details for GUJTERC

Metric Value Recommendation
Overall Rating D+ Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 50.20 Cr 35.48 Cr 14.71 Cr 0.2931 0.00 Cr 1.06 Cr 3.50 Cr -0.98 Cr -1.32 4.19 Cr -0.0195
2024-03-31 47.97 Cr 33.83 Cr 14.14 Cr 0.2948 0.00 Cr 1.07 Cr 0.93 Cr 0.24 Cr 0.33 1.59 Cr 0.0051
2023-03-31 46.78 Cr 40.51 Cr 6.27 Cr 0.1341 0.00 Cr 0.74 Cr -2.08 Cr -1.67 Cr -2.25 -1.81 Cr -0.0357
2022-03-31 40.13 Cr 31.66 Cr 8.47 Cr 0.2111 0.00 Cr 0.77 Cr 0.85 Cr 0.87 Cr 1.18 1.42 Cr 0.0217
2021-03-31 25.18 Cr 23.19 Cr 1.98 Cr 0.0788 0.00 Cr 0.73 Cr -2.75 Cr -2.52 Cr -3.40 -1.97 Cr -0.1001

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.78 Cr 22.83 Cr 16.35 Cr 6.4775 Cr 0.94 Cr 0.16 Cr 3.68 Cr 3.65 Cr 0.00 Cr 0.00 Cr 2.24 Cr 12.6431 Cr
2024-03-31 0.09 Cr 23.27 Cr 16.17 Cr 7.1061 Cr 3.87 Cr 3.78 Cr 4.17 Cr 3.69 Cr 0.00 Cr 0.00 Cr 0.27 Cr 12.1416 Cr
2023-03-31 2.03 Cr 28.72 Cr 21.86 Cr 6.8627 Cr 7.27 Cr 5.24 Cr 4.54 Cr 3.99 Cr 0.06 Cr 1.90 Cr 2.32 Cr 16.6080 Cr
2022-03-31 0.01 Cr 27.56 Cr 19.03 Cr 8.5343 Cr 6.67 Cr 6.66 Cr 6.46 Cr 4.29 Cr 0.09 Cr 1.93 Cr 2.68 Cr 13.2136 Cr
2021-03-31 1.29 Cr 21.80 Cr 14.14 Cr 7.6620 Cr 4.74 Cr 3.45 Cr 3.74 Cr 2.45 Cr 0.00 Cr 0.87 Cr 2.62 Cr 11.6418 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 2.8997 Cr 0.1993 Cr -2.4096 Cr 0.0000 Cr 0.6894 Cr 0.7794 Cr 0.0000 Cr -0.9787 Cr -2.9247 Cr 0.0000 Cr 0.2507 Cr
2024-03-31 2.5997 Cr -0.4579 Cr -4.0816 Cr 2.5260 Cr -1.9398 Cr 0.0901 Cr -0.0737 Cr 0.2434 Cr -3.4056 Cr 0.0000 Cr 0.4449 Cr
2023-03-31 -0.3402 Cr 0.2606 Cr 0.6003 Cr -0.4033 Cr 2.0207 Cr 2.0299 Cr -0.0631 Cr -1.6716 Cr 0.6003 Cr 0.0000 Cr 2.0011 Cr
2022-03-31 -0.5568 Cr -2.6551 Cr 1.9346 Cr -2.6709 Cr -1.2772 Cr 0.0092 Cr -2.1141 Cr 0.8723 Cr 1.9346 Cr 0.0000 Cr -2.6915 Cr
2021-03-31 -0.4133 Cr -0.4625 Cr 2.1205 Cr -0.9177 Cr 1.2447 Cr 1.2864 Cr -0.5044 Cr -2.5202 Cr 2.1413 Cr 0.0000 Cr -0.3063 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 10.85 Cr 4.42 Cr 6.43 Cr 0.5927 -0.12 Cr -0.04 Cr -0.06 0.07 Cr -0.0040
2025-03-31 12.32 Cr 5.51 Cr 6.82 Cr 0.5531 0.95 Cr -3.39 Cr -4.58 1.14 Cr -0.2752
2024-12-31 12.68 Cr 4.48 Cr 8.20 Cr 0.6466 1.00 Cr 1.01 Cr 1.36 1.16 Cr 0.0795
2024-09-30 13.30 Cr 4.21 Cr 9.09 Cr 0.6834 1.57 Cr 1.48 Cr 2.00 1.74 Cr 0.1114
2024-06-30 11.89 Cr 4.71 Cr 7.18 Cr 0.6039 -0.01 Cr -0.08 Cr -0.10 0.15 Cr -0.0065

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 0.78 Cr 0.51 Cr 1.29 Cr 5.24 Cr 3.68 Cr 12.02 Cr 3.65 Cr 22.83 Cr 16.35 Cr
2024-12-31 0.00 Cr 0.00 Cr 0.09 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -8.86 Cr
2024-09-30 0.09 Cr 0.00 Cr 0.09 Cr 7.90 Cr 3.76 Cr 13.13 Cr 3.68 Cr 24.84 Cr 15.98 Cr
2024-06-30 0.00 Cr 0.00 Cr 0.09 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -7.11 Cr
2024-03-31 0.09 Cr 0.00 Cr 0.09 Cr 5.66 Cr 3.98 Cr 11.22 Cr 3.69 Cr 23.27 Cr 16.17 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2024-12-31 1.01 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 1.48 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 -0.08 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 0.54 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-12-31 0.67 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹764.30 ₹91,520,107,617.00 ₹114,608.00

Key Executives

Executive Officer
Praveen Kumar Parmar

Gender: Not Specified

Year Born: 1984

Executive Officer
Sunitha R. Ajmeer

Gender: Not Specified

Year Born: 1972

Founder & Chairman
Mr. Natwarbhai Purshottamdas Prajapati

Gender: male

Year Born: 1952

Chief Executive Officer, MD & Whole Time Director
Mr. Aalap Natubhai Prajapati

Gender: male

Year Born: 1988

Executive Officer
Nirmal Kant Sharma

Gender: Not Specified

Year Born: 1975

Executive Officer
Rajendra Joshi

Gender: Not Specified

Year Born: 1979

Whole Time Director
Mr. Amritbhai Purshottamdas Prajapati

Gender: male

Year Born: 1954

Executive Officer
Narayanlal Suthar

Gender: Not Specified

Year Born: 1975

Executive Officer
Deepak Bhatnagar

Gender: Not Specified

Year Born: 1974

Executive Officer
Shashi Prakash

Gender: Not Specified

Year Born: 1975

FAQs about Gujarat Terce Laboratories Limited

Who is the CEO of the company?

The CEO is Aalap Natubhai Prajapati.

What is the current market price of the stock?

The current price is ₹42.41.

What is the 52-week price range?

The range is ₹37.2-88.6.

What is the market capitalization of the company?

The market capitalization is ₹31.47 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is -32.55.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Gujarat Terce Laboratories Limited (ISIN: INE499G01013) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹31.47 crores and an average daily volume of 6,780 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.